My­ovant adds re­l­u­golix da­ta in uter­ine fi­broids ahead of June PDU­FA; Mubadala teams up with UK for $1B+ fund

As My­ovant bar­rels to­ward its PDU­FA date for re­l­u­golix in uter­ine fi­broids, the biotech is beef­ing up its da­ta pack­age with new Phase III re­sults.

A Phase III ran­dom­ized with­draw­al study met its pri­ma­ry end­point and all sec­ondary end­points, My­ovant and Pfiz­er an­nounced Wednes­day morn­ing, eval­u­at­ing a once-dai­ly re­l­u­golix com­bo ther­a­py with estra­di­ol and norethin­drone ac­etate. The FDA has marked June 1 down on the cal­en­dar for a reg­u­la­to­ry de­ci­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER